Expression of eNOS in kidneys from hypertensive patients by Gu, Xin & Herrera, Guillermo A
© 2010 Gu and Herrera, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nephrology and Renovascular Disease
International Journal of Nephrology and Renovascular Disease 2010:3 11–19 11
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
O R I G I N A L   R e s e A R c H
expression of eNOs in kidneys from hypertensive 
patients
Xin Gu  
Guillermo A Herrera
1Department of Pathology, Louisiana 
state University Health sciences 
center, shreveport, LA, UsA; 
2Nephrocor, Bostwick Laboratories, 
Tempe, AZ, UsA
correspondence: Xin Gu 
Department of Pathology, Louisiana state 
University Health sciences center,  
1501 Kings Highway, shreveport,  
LA 71130, UsA 
email xgu@lsuhsc.edu
Abstract: Endothelium-derived nitric oxide (NO) is essential for maintenance and regula-
tion of blood pressure. In animal models, altered endothelium-derived nitric oxide synthase 
(eNOS) expression and impaired NO generation are important factors for renal injury. However, 
the pattern of eNOS expression in the kidneys from hypertensive patients has not been well 
established. We have studied the eNOS immuno-expression in kidney biopsies from hyperten-
sive patients. Compared to kidneys from normotensive individuals, there were no significant 
alterations of eNOS immuno-expression in the vasculature of patients with chronic essential 
hypertension. In contrast, the expression of eNOS was significantly decreased in the glomeruli 
and arterioles/small arteries of patients with malignant hypertension, particularly in those with 
significant intimal edema and myxoid degeneration or thrombi. Endothelial dysfunction is an 
important pathogenetic factor for chronic primary hypertension and eNOS plays a major role 
in the regulation of vascular tone and function. Unchanged eNOS in the kidney vasculature in 
chronic primary hypertension indicates that these patients have an ability to compensate. In 
patients with malignant hypertension, the expression of eNOS protein was diminished in the 
injured vasculature. Loss of the compensatory mechanism via continued release of NO to 
prevent vascular injury may be responsible for morphological changes typically seen in the 
renal vasculature in patients with accelerated hypertension.
Keywords: endothelium-derived nitric oxide, kidney, chronic hypertension, animal models
Introduction
Primary or essential hypertension is characterized by chronically elevated blood pres-
sure of unknown etiology. This is one of the most important risk factors for developing 
chronic kidney disease. Normal renal blood flow in concert with the renal angiotensin 
system plays a critical role in the maintenance of physiological hemostasis and adjust-
ment of blood pressure. The importance of the endothelial isoform of nitric oxide syn-
thase (eNOS) in maintaining normal renal hemodynamics has been well established.1–4 
Endothelial function is mainly dependent on the generation and bioavailability of NO 
produces by eNOS. In animal studies, reduced NO level is a common denominator 
of many hypertensive models5,6 and direct inhibition of intrarenal NO produce an 
increase in blood pressure.7 Impaired endothelial NO generation is considered one of 
the important factors associated with hypertension and atherosclerosis that result in 
progressive renal injury.8,9 In addition, expression of eNOS and bioavailability of NO 
may be altered by a variety of signal transduction molecules, receptors for growth 
factors, and cytokines.10,11 In animal models, enhanced expression of eNOS has been 
shown to be associated with resistance to hypertensive stimulation.12–14International Journal of Nephrology and Renovascular Disease 2010:3 12
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As an important modulator of renal function and morphol-
ogy, the NO system has been extensively studied in the animal 
models and clinical settings. However, despite increasing 
evidence for the role of eNOS and NO, little is known about 
eNOS expression in the human kidneys in patients who had 
long-standing hypertension. The main objective of this study 
is to use immunohistochemical methods to investigate the 
expression of eNOS in the kidneys from patients with chronic 
primary hypertension, and alterations of eNOS expression in 
patients with chronic essential hypertension who developed 
accelerated or malignant hypertension.
Materials and methods
selection of cases and tissue processing
Normal kidney controls were collected from five adult nor-
motensive patients who had nephrectomy for excision of 
renal neoplasms. The control specimens were collected from 
renal parenchyma that was uninvolved by neoplasms (renal 
cell carcinomas). Six kidney biopsies from adult patients with 
chronic primary hypertension and five kidney biopsies from 
patients with malignant hypertension were retrospectively 
identified from our archives of kidney biopsies.
All kidney biopsies were processed for light micros-
copy, direct immunofluorescence, and electron microscopy 
according to standard techniques.15,16 The controls were 
processed for light microscopy only. No immunofluores-
cence or electron microscopic evaluation was performed in 
these samples.
Immunohistochemistry
Immunohistochemical stains were performed on formalin-fixed, 
paraffin-embedded tissue sections. A standard immunohisto-
chemistry staining procedure was performed as we previously 
described.17 Briefly, deparaffinization was performed using 
xylene and ethanol. Antigen retrieval was achieved by boil-
ing tissue slides with 0.01 M citric buffer in a microwave 
for five minutes. Hydrogen peroxide was used to quench the 
endogenous peroxidase activity.
After blocking with 10% serum-tris buffer for 20 minutes 
at room temperature, the sections were incubated with primary 
polyclonal anti-eNOS antibody (1:50 dilution in Tris buffer; 
Abcam, Cambridge, MA) at room temperature for 120 minutes. 
Corresponding biotinylated conjugated secondary antibody 
from Dako staining system was used. Slides stained with 
secondary antibody only were used as negative controls. The 
nuclei were counterstained with hematoxylin.
The intensity of immunostaining for eNOS in endothelial 
cells was evaluated on a 0 to 3+ scale (0, no staining; 1+, weak 
staining; 2+, moderate – easily identified in the cytoplasm 
using high magnification – 60×; and 3+, strong staining that 
was easily identified from low power magnification – 20×).
Results
clinical data
All kidney specimens were from adult patients (aged 24 to 
76 years). In the control group, the patients had no known 
clinical history of hypertension. Their pre-operative blood 
pressures were within normal limits.
The clinical data from the control group and from, patients 
with chronic primary and malignant hypertension are sum-
marized in Table 1. All patients in the chronic hypertension 
group had a history of primary hypertension for more than 
five years. The biopsies were performed for deterioration of 
renal function with or without proteinuria. All patients with 
malignant hypertension had a history of hypertension for at 
least two years. Three of these patients presented with sud-
den onset of headache, nausea, elevated blood pressure over 
210/120 and, variable degrees of renal insufficiency. One 
presented to the emergency room with an infectious process 
and was incidentally identified with accelerated hypertension 
(blood pressure = 190/110) and an elevated serum creatinine. 
Another patient had blurry vision and was found to have 
markedly elevated blood pressure (over 210/120), as well as an 
increased serum creatinine. In both primary hypertension and 
malignant hypertension groups, laboratory work up revealed 
negative serology tests, including anti-nuclear antibodies 
(ANA) and antineutrophilic cytoplasmic antibodies (ANCA). 
They had all been in treatment with a variety of antihyperten-
sion medications for variable periods of time.
Pathology findings
Control kidneys were normal. There was no significant 
interstitial fibrosis, tubular atrophy or thickening of vascular 
intima. The glomeruli showed open loops. The capillary walls 
were thin and smooth (Figure 1A). There was no fibrinoid 
thickening of the intima of arteriole and interlobular arteries 
(Figure 2A). The kidneys from patients in the chronic primary 
hypertensive group showed patchily distributed interstitial 
fibrosis associated with tubular atrophy and drop out. Scat-
tered lymphocytes were often present in association with 
areas with interstitial fibrosis. The viable glomeruli showed 
retraction of capillary tufts with segmental thickening and 
wrinkling of capillary loops (Figure 1B). The interlobular 
arteries revealed intimal fibrous thickening and the arterioles 
showed thickening of their walls with segmental hyalinosis 
(Figure 2B). Except for the vascular disease-associated International Journal of Nephrology and Renovascular Disease 2010:3 13
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changes, there was no morphologic evidence of a specific 
glomerular disorder, such as proliferative glomerulonephritis, 
immune complex mediated glomerulonephritis or diabetic 
glomerulopathy. There was no evidence of tubular necrosis 
or interstitial nephritis. Ultrastructurally, segmental wrin-
kling and thickening of capillary basement membranes were 
common in glomeruli. There were no significant endothelial 
structural alterations. No immune complexes or paraprotein 
deposits were identified in any of the renal compartments in 
any of these cases.
In patients with malignant hypertension, the interstitium 
revealed similar findings as in the chronic hypertensive 
patients, but more pronounced. In the glomeruli, the mor-
phologic findings were variable. Some glomeruli revealed 
typical features of thrombotic microangiopathy with seg-
mental fibrinoid necrosis of capillary tufts (Figure 1C). Some 
glomeruli showed widening of subendothelial spaces and 
mesangiolysis, while other glomeruli were essentially unre-
markable under light microscopic evaluation. The pathologic 
findings in the glomeruli were often highlighted by periodic 
acid-Schiff (PAS) and silver methenamine stains that stained 
basement membranes.15,16 The arterioles and small arteries 
revealed significant intimal thickening and myxoid change 
(Figure 2C). Hyperplastic arteriolopathy (“onion-skinning”) 
was present in all cases, and arteriolar fibrinoid necrosis was 
identified in two cases (Figure 1C). By electron microscopy, 
there was widening of subendothelial spaces with electron 
lucent fluffy-appearing material in the glomeruli. Mesan-
giolysis, fragmented platelets and red blood cells, and fibrin 
were identified in the subendothelium in some glomeruli 
(Figure 1D).
expression of eNOs
In the control group (Figure 3A), moderate to strong (3+) 
expression of eNOS was present in the cytoplasm of endothe-
lial cells in glomeruli, arterioles, interlobular arteries, veins 
and peritubular capillaries (Figure 4A). In the glomeruli, 
there was no immunoreaction in mesangial cells. The vis-
ceral epithelial cells that were also negative for eNOS. Weak 
staining along tubular basement membranes and cytoplasm 
of some tubular epithelial cells (0 to 1+) was noted in focal 
areas. The interstitial cells and inflammatory cells were 
negative for eNOS.
The expression of eNOS in biopsies from primary 
hypertensive patients revealed similar findings as that in the 
controls. There was no significant difference in the patterns 
of expression and the intensity of immunoreaction in glom-
eruli (Figure 3B), arterioles, and small arteries (Figure 4B). 
In the interstitium, when there were dense lymphocytic 
infiltrates, the peritubular capillaries in the nearby areas 
Table 1 Demographic and clinical data
Control (5 cases) Chronic hypertension (6 cases) Malignant hypertension (5 cases)
Age, mean ± sD 57.6 ± 3.6 Age, mean ± sD 58.7 ± 11.9 Age, mean ± sD 41.6 ± 11.9
Age, range 53 to 63 Age, range 41 to 76 Age, range 24 to 55
sex, male/female 3/2 sex, male/female 4/2 sex, male/female 4/1
Proteinuria Proteinuria Proteinuria
  Trace 0   Trace 2   Trace 1
  Nonnephrotic 0   Nonnephrotic 2   Nonnephrotic 2
  Nephrotic 0   Nephrotic 0   Nephrotic 0
  Data not available 0   Data not available 2   Data not available 2
serum creatinine (mg/dL) serum creatinine (mg/dL) serum creatinine (mg/dL)
  Normal 5   Normal 2   Normal 0
  Abnormal 0   Abnormal 2 (less than 2)   Abnormal 4 (3.7 to 12)
  Data not available 0   Data not available 2   Data not available 1
Microhematuria 0 Microhematuria 0 Microhematuria 2
  Data not available   Data not available   Data not available 3
History of cRI* 0 History of cRI 0 History of cRI 2
  Data not available   Data not available   Data not available 3
Blood pressure Blood pressure Blood pressure
  Above 140/90 0   Above 140/90 6   systolic 190 to 220
  Diastolic 110 to 140
Abbreviation: CRI, chronic renal insufficiency.International Journal of Nephrology and Renovascular Disease 2010:3 14
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expressed relatively strong immunoreactivity for eNOS when 
compared to the capillaries that were not associated with the 
surrounding interstitial inflammation.
In patients with malignant hypertension, the expres-
sion of eNOS was significantly attenuated in the glomeruli 
(Figure 3C), arterioles and small arteries. In the glomeruli and 
arterioles that showed prominent intima edema or fibrinoid 
thrombi, eNOS expression was diminished (Figure 4C). 
The patterns and intensity of eNOS in the tubulointersi-
tium appeared similar to that in the chronic hypertensive 
patients.
Discussion
Primary hypertension is a common disease. Uncontrolled 
hypertension is one of the most important risk factors for 
cardiovascular disease, stroke and sudden death. Chronic 
hypertension is also a leading cause for developing end-stage 
renal disease. Malignant hypertension may suddenly appear 
in patients with chronic hypertension and is life threatening. 
Renal endothelial cell integrity and vascular homeostasis play 
a critical role in monitoring and maintaining normal vascular 
tone and blood pressure.1,9
In general, vascular endothelial cells release NO 
under normal (basal) conditions as a result of shear stress 
exerted by the circulating blood. The released NO dif-
fuses to the underlying vascular smooth muscle cells and 
activates soluble guanylate cyclase, leading to an increase 
in cGMP resulting in relaxation.18,19 Together with vaso-
constrictive mediators, renal endothelial cell-derived NO 
plays a critical role in regulation of renal blood flow and 
A B
C D
Figure 1 Glomeruli. A) Glomerulus from control kidney. B) Glomerulus from patient with chronic hypertension. The glomerulus revealed retraction of capillary tufts and 
segmental wrinkling of membranes. C) Glomerulus from patient with malignant hypertension. The glomerulus showed segmental fibrinoid necrosis of capillary tufts. Micro-
thrombus was present in the arteriole. D) electron microscopy of glomerulus from patient with malignant hypertension. There was widening of subendothelial spaces with 
accumulation of fragmented platelets and fibrin.International Journal of Nephrology and Renovascular Disease 2010:3 15
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glomerular filtration rate. Endothelial NOS produced NO is 
also responsible for modulation of angiotensin II-mediated 
renal norepinephrine release.4,20 In addition, NO released 
from endothelial cell also has antiplatelet, antiproliferation, 
and anti-inflammatory properties.21,22
It has been well documented that renal endothelial 
dysfunction, characterized by decreased production or 
bioavailability of NO, is associated with the pathogenesis 
of hypertension. In animal models, lower levels of eNOS 
activity resulted in vasoconstriction with an increase in 
blood pressure.23,24 Low NO levels were also associated with 
vascular hypertrophy, intimal thickening, and reduced vas-
cular lumina.25 Studies performed in humans have indicated 
that hypertension is associated with selective impairment of 
endothelium-dependent vasodilation.9
Expression of eNOS and production of NO are regulated 
at multiple levels and through different pathways. Shear 
stress is the major factor for inducing eNOS upregulation. 
In contrast, hypoxia, tumor necrosis factor-α, and oxygen 
radicals downregulate eNOS expression.1,11 Second messen-
ger systems, intracellular calcium and phosphorylation are 
involved in regulation of eNOS.1,26 In addition, NO bioavail-
ability is also adjusted by the rate of scavenger activity, such 
as regional radical oxygen species.8
Although plenty of data have been generated support-
ing that deficiency of eNOS and bioavailability of NO are 
related to the development of hypertension and persistence 
of elevated blood pressure, in most instances the information 
was obtained from animal models or in vitro studies. There 
is little information on eNOS expression in the kidneys in 
Figure 2 small arteries. A) A small artery in control kidney. B) A small artery in the kidney from patient with chronic hypertension. The artery showed thickening and hyalinosis 
of vascular wall. C) A small artery in the kidney from patient with malignant hypertension. The artery revealed significant thickening of vascular wall, myxoid degeneration of 
intima and obliteration of lumen. The endothelial cells showed edema with enlarged nuclei and pale cytoplasm.International Journal of Nephrology and Renovascular Disease 2010:3 16
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patients with long-term chronic hypertension. In this study, 
we have detected eNOS protein expression in the kidneys 
in patients with chronic primary hypertension, as well as in 
chronic hypertensive patients who had developed accelerated 
or malignant hypertension.
In this immunohistochemical study, moderate to strong 
(2–3+) eNOS expression was identified in the endothelial 
cells in all locations, including glomeruli, arterioles, small 
arteries, interlobular arteries and veins as well as peritubular 
capillaries (Figures 3A, 4A). There was no significant dif-
ference in terms of intensity of immuno-expression in the 
different-sized vessels. Compared to the normal control 
group, there was no alteration of eNOS expression in the 
glomeruli (Figure 3B) and vessels from patients with chronic 
primary hypertension (Figure 4B). In both groups, there was 
moderate to strong eNOS immunoreaction in the endothelial 
cells. However, the expression of eNOS was attenuated in 
the endothelial cells in the glomeruli and arterioles from 
patients with malignant hypertension. Only minimal to 
mild immunoreactivity (1+) was noted in the glomeruli 
(Figure 3C) and arterioles in the kidneys from patients 
in malignant hypertension. Moderate immunoreactivity 
for eNOS was only occasionally identified in glomerular 
epithelial cells. In the vasculature exhibiting microthrombi 
and fibrinoid necrosis, the eNOS immunoreactivity was 
markedly diminished (Figure 4C).
Glomerular endothelial cells are often injured in patients 
with malignant hypertension. Histologically, glomerular 
segmental fibrinoid necrosis with or without microthrombi 
may be seen associated with the characteristic hyperplastic 
arteriolopathy. The glomeruli without significant light micro-
scopic changes may also reveal endothelial cell injury that 
can be only detected at the ultrastructural level, including 
edema of endothelial cells, fragmentation of the cytoplasm 
Figure 3 expression of eNOs in the glomeruli. A) control. B) chronic hypertension. C) Malignant hypertension.International Journal of Nephrology and Renovascular Disease 2010:3 17
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and accumulation of electron lucent material in the suben-
dothelial spaces. In addition, immunoreactivity for receptors 
and important enzymes may also be altered, as we recently 
reported in kidney biopsies from pregnant women with sig-
nificantly elevated blood pressures.17
These results suggest that, compared to the control group, 
there is no alteration of eNOS protein expression in chronic 
primary (essential) hypertension. However, expression of 
eNOS is attenuated in association with accelerated (malig-
nant) hypertension. The attenuated expression of eNOS 
is most likely related to more severe endothelial injury in 
malignant hypertension cases.
In this study, the control specimens were collected from 
nephrectomy kidney from patients with neoplasms. The 
specimens were taken at some distance from the neoplasms 
as previous studies reported.27,28 Except for uncommon 
neoplasms (renal juxtaglomerular cell tumor and carcinoid 
tumor), renal neoplasms do not affect systemic circulation 
and blood pressure. As seen in Table 1, the age range in 
hypertensive patients was broad. This may reflect the fact 
that hypertension is a common disease and affects a wide 
range of the population. In both primary and malignant 
hypertension groups, patients had renal function dysfunction 
and presented with variable degrees of proteinuria and/or 
elevated serum creatinine. The pathological findings from 
these patients are more likely due to persistent hypertension 
rather than merely aging.
Protein expression does not necessarily correlate with 
enzyme activity and NO production. In chronic primary 
hypertensive patients, dysfunction of renal endothelial 
cells, alteration in NO synthesis, and release may occur 
mainly post-transcriptionally, resulting from such pro-
cesses as abnormal phosphorylation, uncoupling with sec-
ond messenger systems, and NO scavenging, as has been 
Figure 4 expression of eNOs in the arteries. A) control. B) chronic hypertension. C) Malignant hypertension. The marker was in the center of the artery that revealed 
myxoid degeneration of intima and injured endothelial cells.International Journal of Nephrology and Renovascular Disease 2010:3 18
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suggested in previous studies performed in animal models 
and hypertensive patients.29,30 Genetic polymorphism of 
eNOS may also contribute to reduced bioavailability of NO, 
as recent studies have suggested.31,32 In the biopsies from 
malignant hypertension patients, the expression of eNOS was 
decreased in the injured vasculature.
Based on this study, we assume that in chronic essential 
hypertension it is likely that eNOS-derived NO remains at 
a critical (minimal) level which maintains hemodynamic 
balance. In this condition the endothelial cells are dysfunc-
tional and their compensatory ability is limited. Factors that 
trigger unbalanced NO bioavailability induce rapid blood 
pressure elevation, as has been demonstrated in studies per-
formed on spontaneously hypertensive rats.33 The decrease 
of bioavailable NO further precipitates endothelial injury, 
platelet aggregation with formation of microthrombi, and 
endothelial cell necrosis, as has been reported to occur 
in some glomerulonephritis in human studies and animal 
models.28,34,35 The totally absent eNOS immunoreactivity in 
the severe form of thrombotic angiopathy was most likely a 
consequence of endothelial cell necrosis.
Previous studies have also indicated that inducible 
NOS (iNOS) is present in the kidneys. The expression 
of iNOS has been documented in tubular epithelial and 
inflammatory cells. Inducible-NOS has also been shown in 
mesangial cells after exposure to cytokines or endotoxins, 
but not in the normal renal tissue.35,36 The expression of 
iNOS has been demonstrated to be significantly increased 
in the glomeruli in lupus nephritis and in experimental 
antimyeloperoxidase-associated crescentic glomeruli-
tis.35,37,38 In transplant kidneys, iNOS has been shown 
to participate in ischemia-reperfusion-induced tubular 
and glomerular injury.39,40 In these conditions, excessive 
amount of NO was generated by iNOS and increased NO 
radical production resulted in tissue injury, as revealed 
in experimental animal models. In general iNOS is not 
directly involved in the pathophysiology of hypertension 
or in adjusting vascular tone in the kidney.
Clinically, hypertension is treated with a variety of 
medications, such as diuretics, calcium-channel blockers 
and angiotensin-converting enzyme inhibitors. Some of these 
medications may affect NO bioavailability,41 however, there 
is no evidence that these medications affect eNOS expres-
sion. In recent studies, effective delivery of NOS gene to 
endothelial cells has demonstrated therapeutic benefits in the 
animal models.42,43 These studies suggest that enhancement 
of eNOS expression though gene therapy may be a useful 
therapeutic modality for hypertension.
In conclusion, eNOS plays a major role in the regulation 
of vascular tone and function, and endothelial dysfunction 
is an important pathogenetic factor for chronic primary 
hypertension. Endothelial NOS was unchanged in the kidney 
vasculature at the protein level in patients with chronic pri-
mary hypertension. In patients with malignant hypertension, 
the expression of eNOS protein was decreased or diminished 
in the injured glomeruli, small renal arteries and arterioles. 
In these patients, enhanced vasoconstrictive response and 
loss of compensatory mechanisms (via continued NO release 
from endothelial cells to prevent vascular injury and rapid 
acceleration) may be responsible for progression into malig-
nant hypertension.
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